The federal crackdown on DEI initiatives is unlikely to deter companies from designing more representative trials, as it’s ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Pfizer said on Monday former head of the US Food and Drug Administration's drug center, Patrizia Cavazzoni, will join the ...

The former head of the Food and Drug Administration’s (FDA) drug division is joining Pfizer as its chief medical officer, the ...

A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

GSK said Dr. Jesse Goodman will retire from the board of directors after nine years. Bryan Supran, non-executive director and representative of Pfizer, stepped down from the Haleon board of directors.

Summit’s PD-1 bispecific antibody outperformed MSD’s Keytruda in a Phase III trial enrolling patients with lung cancer.

We recently compiled a list of the Jim Cramer Remembers COVID-19 & Discusses These 11 Stocks. In this article, we are going ...

Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...